- Home
- GITS vs PHGE Comparison
GITS vs PHGE Comparison
Compare GITS & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GITS | PHGE |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | South Korea | United States |
| Employees | 12 | 57 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 9.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GITS | PHGE |
|---|---|---|
| Price | $2.41 | $2.89 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 35.8K | ★ 76.7K |
| Earning Date | 05-19-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.25 |
| 52 Week High | $7.09 | $8.50 |
Technical Indicators
Market Signals| Indicator | GITS | PHGE |
|---|---|---|
| Relative Strength Index (RSI) | 46.83 | 32.43 |
| Support Level | $2.08 | $0.42 |
| Resistance Level | $2.40 | $5.87 |
| Average True Range (ATR) | 0.25 | 0.58 |
| MACD | -0.01 | -0.19 |
| Stochastic Oscillator | 23.29 | 10.01 |
Price Performance
Historical ComparisonAbout GITS Global Interactive Technologies Inc.
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).